Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | PRKDC | P78527 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13740087 | 0.94 | CYP1A2 (0.45) | GRM5MAPK1HSD17B10MEN1KMT2A | |
| SCHEMBL13739293 | 0.93 | MAPT (0.46) | GRM5MAPK1HSD17B10MEN1KMT2A | |
| SCHEMBL13826287 | 0.93 | MAPT (0.46) | GRM5MAPK1HSD17B10MEN1KMT2A | |
| SCHEMBL13826279 | 0.92 | PDE10A (0.43) | GRM5MAPK1HSD17B10MEN1KMT2A | |
| SCHEMBL13826277 | 0.92 | GRM5 (0.41) | GRM5MAPK1HSD17B10MEN1KMT2A | |
| SCHEMBL13740886 | 0.92 | PDE10A (0.43) | GRM5MAPK1HSD17B10MEN1KMT2A | |
| SCHEMBL13739590 | 0.90 | ADORA1 (0.47) | GRM5MAPK1HSD17B10MEN1KMT2A | |
| SCHEMBL13826497 | 0.89 | PIK3CD (0.43) | GRM5MAPK1HSD17B10MEN1KMT2A | |
| SCHEMBL13826369 | 0.89 | MAPT (0.48) | MEN1KMT2AMAPTPIK3CDPIK3CA | |
| SCHEMBL13737390 | 0.89 | GRM5 (0.48) | GRM5MAPK1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2022011091-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-10307422-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10307422-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | USHER III INITIATIVE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2018-07-26 | — | — | US | disclosed |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2018-07-26 | — | — | US | disclosed |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | BIOFOCUS DPI LTD. (GB) | 2018-07-26 | — | — | US | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE, INC. | 2018-04-12 | — | — | US | disclosed |
| US-8765762-B2 | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome | Usher III, Initiative, Inc. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765762-B2 | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome | Usher III, Initiative, Inc. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140121197-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. | 2014-05-01 | — | — | US | disclosed |
| US-20140121205-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121205-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2014-05-01 | — | — | US | disclosed |
| WO-2014066835-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20130252936-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252936-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252936-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012148994-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | USHER III INITIATIVE (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121205-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, PSEN2 | GRM5 2046/4885MAPK1 3201/4885HSD17B10 4272/4885 |
| US-20180099974-A1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | PSMG3, HSPA5, TTR | GRM5 3816/4885MAPK1 4195/4885HSD17B10 2968/4885 |
| US-20180207159-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | GRM5 1706/4885MAPK1 2340/4885HSD17B10 3759/4885 |
| US-20140121197-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | GRM5 1706/4885MAPK1 2340/4885HSD17B10 3759/4885 |
| US-10307422-B2 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome | ALDH1A2, ALDH1A3, NR2E3 | GRM5 1706/4885MAPK1 2340/4885HSD17B10 3759/4885 |
| US-20130252936-A1 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME | ALDH1A2, ALDH1A3, NR2E3 | GRM5 1706/4885MAPK1 2340/4885HSD17B10 3759/4885 |
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | GRM5 1709/4885MAPK1 2793/4885HSD17B10 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.